Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Petróleo Brasileiro SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Petróleo Brasileiro SA trades at $17.46 (market cap $105.14B). The key difference: Petróleo Brasileiro SA is far larger — about 2.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Petróleo Brasileiro SA pays a 10.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PBR | |
|---|---|---|
Market Cap | $39.89B | $105.14B |
Sector | Health | Technology |
52-Week High | $491.22 | $22.03 |
52-Week Low | $278.09 | $11.54 |
Enterprise Value | $38.15B | $167.68B |
Dividend Yield | — | 10.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Petrobras (PBR) trades at $17.32, up 1.7% with bullish technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 5.52 and ROE of 24.94%, supported by robust cash flow generation of $197.5B in 2025. Recent developments include strategic partnerships with Pemex and renewable energy investments, while maintaining consistent dividend payments.
PBR presents compelling value with significant upside to the $23.90 consensus target, though faces risks from commodity volatility and recent earnings miss. The company's production growth and cost discipline support long-term investment case, but investors should monitor execution on new projects and oil price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
